{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T23:01:23Z","timestamp":1771801283624,"version":"3.50.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bortezomib, a proteasome inhibitor (PI), has shown efficacy in the treatment of newly diagnosed and relapsed light chain (AL) amyloidosis, and is often used in combination with cyclophosphamide and dexamethasone. Ixazomib is the first oral PI to be approved in routine practice but has not yet been evaluated in the upfront treatment setting. Newly diagnosed AL amyloidosis patients with measurable disease and adequate organ function were enrolled. The primary objective was to determine the hematologic response rate of ixazomib in combination with cyclophosphamide and dexamethasone. Treatment was given for 12 cycles, followed by ixazomib maintenance until progression. Thirty-five patients were included; their median age was 67 years, and 69% were male. Major organ involvement included heart (66%) and kidneys (54%). A median of 4 induction cycles (range, 1-12) were administered. The overall hematologic response to induction was 63% and included complete response in 11.4% and very good partial response in 37.1% of patients. One patient was upstaged to complete response during maintenance. The most common reason for going off study was the institution of alternate therapy (61%). With a median follow-up of 29.7 months for the living patients, the 2-year progression-free survival and overall survival were 74% and 78%, respectively. The median time to alternate therapy was 7.5 months. Grade \u22653 hematologic and nonhematologic adverse events occurred in 23% and 49% of patients. Given ixazomib\u2019s favorable toxicity profile, which is an important advantage for the typically frail AL population, further evaluation of ixazomib in other combinations in the upfront setting is warranted. This trial was registered at www.clinicaltrials.gov as #NCT01864018.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007781","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T18:53:12Z","timestamp":1656010392000},"page":"5429-5435","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"first","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy R.","family":"LaPlant","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"},{"name":"3Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-8212","authenticated-orcid":false,"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi Lisa","family":"Hwa","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dania K.","family":"Helgeson","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin E.","family":"Bradt","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1559","authenticated-orcid":false,"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-7311","authenticated-orcid":false,"given":"Mustaqueem","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy T.","family":"Larsen","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"issue":"1","key":"2022092315285629000_B1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA."},{"issue":"8","key":"2022092315285629000_B2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res."},{"issue":"23","key":"2022092315285629000_B3","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2022092315285629000_B4","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"15","key":"2022092315285629000_B5","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood."},{"issue":"9","key":"2022092315285629000_B6","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2022092315285629000_B7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J Intern Med."},{"issue":"6","key":"2022092315285629000_B8","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc."},{"key":"2022092315285629000_B9","doi-asserted-by":"crossref","first-page":"100581","DOI":"10.1016\/j.blre.2019.05.005","article-title":"Use of novel therapies in the treatment of light chain amyloidosis","volume":"37","author":"Varga","year":"2019","journal-title":"Blood Rev."},{"issue":"28","key":"2022092315285629000_B10","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol."},{"issue":"25","key":"2022092315285629000_B11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood."},{"issue":"19","key":"2022092315285629000_B12","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood."},{"issue":"5","key":"2022092315285629000_B13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood."},{"issue":"15","key":"2022092315285629000_B14","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood."},{"issue":"1","key":"2022092315285629000_B15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"2022092315285629000_B16","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc."},{"issue":"4","key":"2022092315285629000_B17","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1002\/ajh.23936","article-title":"Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies","volume":"90","author":"Kastritis","year":"2015","journal-title":"Am J Hematol."},{"issue":"19","key":"2022092315285629000_B18","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood."},{"issue":"1","key":"2022092315285629000_B19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib-dexamethasone versus physician\u2019s choice in relapsed or refractory AL amyloidosis","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia."},{"issue":"5","key":"2022092315285629000_B20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood."},{"issue":"8","key":"2022092315285629000_B21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-018-0106-3","article-title":"Phase 1\/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma","volume":"8","author":"Kumar","year":"2018","journal-title":"Blood Cancer J."},{"issue":"36","key":"2022092315285629000_B22","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol."},{"issue":"15","key":"2022092315285629000_B23","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood."},{"issue":"11","key":"2022092315285629000_B24","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia."},{"issue":"1","key":"2022092315285629000_B25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10428194.2021.1971215","article-title":"A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis","volume":"63","author":"Palladini","year":"2022","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"2022092315285629000_B26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/13506129.2019.1594759","article-title":"Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study","volume":"26","author":"Shen","year":"2019","journal-title":"Amyloid."},{"issue":"12","key":"2022092315285629000_B27","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia."},{"issue":"4","key":"2022092315285629000_B28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood."},{"issue":"22","key":"2022092315285629000_B29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood."},{"issue":"3","key":"2022092315285629000_B30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/cells10030545","article-title":"Daratumumab in the treatment of light-chain (AL) amyloidosis","volume":"10","author":"Palladini","year":"2021","journal-title":"Cells."},{"issue":"6","key":"2022092315285629000_B31","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.clml.2016.03.005","article-title":"Bortezomib-containing regimens for the treatment of newly diagnosed and relapsed amyloid light chain amyloidosis: a single-center experience","volume":"16","author":"Jimenez-Zepeda","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"6","key":"2022092315285629000_B32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/18\/5429\/1922202\/advancesadv2022007781.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/18\/5429\/1922202\/advancesadv2022007781.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T15:30:21Z","timestamp":1663947021000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/18\/5429\/485685\/Phase-2-trial-of-ixazomib-cyclophosphamide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":32,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,9,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007781","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}